HK1040093B - Method of enhancing the biological activity of ligands - Google Patents

Method of enhancing the biological activity of ligands Download PDF

Info

Publication number
HK1040093B
HK1040093B HK02101186.0A HK02101186A HK1040093B HK 1040093 B HK1040093 B HK 1040093B HK 02101186 A HK02101186 A HK 02101186A HK 1040093 B HK1040093 B HK 1040093B
Authority
HK
Hong Kong
Prior art keywords
ang
cell
nucleic acid
fusion polypeptide
protein
Prior art date
Application number
HK02101186.0A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1040093A1 (en
Inventor
J. Davis Samuel
W. Gale Nicholas
D. Yancopoulos George
Stahl Neil
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HK1040093A1 publication Critical patent/HK1040093A1/en
Publication of HK1040093B publication Critical patent/HK1040093B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02101186.0A 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands HK1040093B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11338798P 1998-12-23 1998-12-23
US113387P 1998-12-23
PCT/US1999/030900 WO2000037642A1 (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Publications (2)

Publication Number Publication Date
HK1040093A1 HK1040093A1 (en) 2002-05-24
HK1040093B true HK1040093B (en) 2005-05-06

Family

ID=22349103

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101186.0A HK1040093B (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Country Status (12)

Country Link
US (1) US7008781B1 (https=)
EP (1) EP1141294B1 (https=)
JP (1) JP4493854B2 (https=)
AT (1) ATE290089T1 (https=)
AU (1) AU776393B2 (https=)
CA (1) CA2354846A1 (https=)
DE (1) DE69924009T2 (https=)
HK (1) HK1040093B (https=)
IL (1) IL143558A0 (https=)
NZ (1) NZ512326A (https=)
PL (1) PL199645B1 (https=)
WO (1) WO2000037642A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
WO2001047951A2 (en) * 1999-12-23 2001-07-05 An-Go-Gen Inc. Angiopoietin analogs
PL366000A1 (en) 2000-08-08 2005-01-24 M.G.V.S.Ltd. Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
WO2003034990A2 (en) 2001-10-25 2003-05-01 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
CA2928852A1 (en) 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
ES2867249T3 (es) 2015-11-06 2021-10-20 Regeneron Pharma Angiopoyetinas para usar en la promoción de la coagulación sanguínea y en el tratamiento de trastornos de la coagulación sanguínea
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547163B1 (en) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
JPH08505765A (ja) 1992-11-13 1996-06-25 アムジエン・インコーポレーテツド Ｅｃｋ受容体リガンド
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
ATE232901T1 (de) * 1994-04-04 2003-03-15 Regeneron Pharma Biologisch aktive ligande der eph familie
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
WO1997015667A1 (en) 1995-10-25 1997-05-01 Regeneron Pharmaceuticals, Inc. Biologically active eph family ligands
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
WO1997023639A1 (en) * 1995-12-22 1997-07-03 Toray Industries, Inc. Process for producing biologically active fused proteins
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
IL127623A0 (en) 1996-06-19 1999-10-28 Regeneron Pharma Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Also Published As

Publication number Publication date
CA2354846A1 (en) 2000-06-29
PL199645B1 (pl) 2008-10-31
DE69924009D1 (de) 2005-04-07
HK1040093A1 (en) 2002-05-24
ATE290089T1 (de) 2005-03-15
JP4493854B2 (ja) 2010-06-30
NZ512326A (en) 2003-11-28
JP2003506008A (ja) 2003-02-18
WO2000037642A9 (en) 2000-11-02
AU2714700A (en) 2000-07-12
PL349158A1 (en) 2002-07-01
WO2000037642A1 (en) 2000-06-29
US7008781B1 (en) 2006-03-07
IL143558A0 (en) 2002-04-21
AU776393B2 (en) 2004-09-09
DE69924009T2 (de) 2006-04-13
EP1141294A1 (en) 2001-10-10
EP1141294B1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
US7309586B2 (en) Chimeric coiled coil molecules
EP1141294B1 (en) Method of enhancing the biological activity of ligands
JP4723140B2 (ja) 改善された薬物動態特性を有する改変キメラポリペプチド
EP2126092B1 (en) Fusion proteins binding to growth factors
US8343737B2 (en) Cell culture compositions capable of producing a VEGF-binding fusion polypeptide
EP0758381B1 (en) Biologically active eph family ligands
US5747033A (en) Method of enhancing the biological activity of Eph family ligands
WO2005058953A2 (en) Ogh fusion polypeptides and therapeutic uses thereof
AU712737B2 (en) Biologically active EPH family ligands
CA2236001C (en) Biologically active eph family ligands

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20191222